{"id": "article-20256_0", "title": "Dapsone -- Continuing Education Activity", "content": "Dapsone is an antibiotic medication\u00a0used in\u00a0multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Initially investigated as an antibiotic agent in 1937, dapsone was first utilized for leprosy treatment in 1945. The drug is also\u00a0prescribed for a range of conditions, including both dermatological and non-dermatological ailments.\u00a0Dapsone is currently available in both oral and topical formulations.", "contents": "Dapsone -- Continuing Education Activity. Dapsone is an antibiotic medication\u00a0used in\u00a0multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Initially investigated as an antibiotic agent in 1937, dapsone was first utilized for leprosy treatment in 1945. The drug is also\u00a0prescribed for a range of conditions, including both dermatological and non-dermatological ailments.\u00a0Dapsone is currently available in both oral and topical formulations."}
{"id": "article-20256_1", "title": "Dapsone -- Continuing Education Activity", "content": "Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis. In addition, the drug demonstrates anti-inflammatory effects.\u00a0The off-label\u00a0uses of dapsone include a broad spectrum of dermatoses, as well as prevention and treatment of malaria and Pneumocystis jiroveci (previously known as Pneumocystis carinii ).\u00a0This activity reviews the indications, mechanism of action, administration, adverse event profile, pharmacodynamics, and monitoring of dapsone pertinent to interprofessional healthcare teams involved in the treatment of conditions where dapsone is indicated.", "contents": "Dapsone -- Continuing Education Activity. Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis. In addition, the drug demonstrates anti-inflammatory effects.\u00a0The off-label\u00a0uses of dapsone include a broad spectrum of dermatoses, as well as prevention and treatment of malaria and Pneumocystis jiroveci (previously known as Pneumocystis carinii ).\u00a0This activity reviews the indications, mechanism of action, administration, adverse event profile, pharmacodynamics, and monitoring of dapsone pertinent to interprofessional healthcare teams involved in the treatment of conditions where dapsone is indicated."}
{"id": "article-20256_2", "title": "Dapsone -- Continuing Education Activity", "content": "Objectives: Differentiate between the FDA-approved and off-label uses of dapsone, recognizing its application in various dermatoses, malaria, and Pneumocystis jiroveci prevention and treatment. Implement appropriate dosing regimens for dapsone in both oral and topical formulations, ensuring optimal therapeutic outcomes. Apply knowledge of dapsone's mechanism of action, combining its antimicrobial and anti-inflammatory effects, to treat diverse dermatologic and non-dermatologic conditions. Collaborate with other healthcare team members to discuss and address any severe adverse effects or challenges patients encounter during dapsone treatment. Access free multiple choice questions on this topic.", "contents": "Dapsone -- Continuing Education Activity. Objectives: Differentiate between the FDA-approved and off-label uses of dapsone, recognizing its application in various dermatoses, malaria, and Pneumocystis jiroveci prevention and treatment. Implement appropriate dosing regimens for dapsone in both oral and topical formulations, ensuring optimal therapeutic outcomes. Apply knowledge of dapsone's mechanism of action, combining its antimicrobial and anti-inflammatory effects, to treat diverse dermatologic and non-dermatologic conditions. Collaborate with other healthcare team members to discuss and address any severe adverse effects or challenges patients encounter during dapsone treatment. Access free multiple choice questions on this topic."}
{"id": "article-20256_3", "title": "Dapsone -- Indications", "content": "Dapsone is an antibiotic medication\u00a0used in\u00a0multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Although dapsone was initially researched as an antibiotic agent in 1937, it was first used to treat leprosy in 1945. [1] This drug is available in oral and topical formulations and is also\u00a0prescribed for a range of conditions, including both dermatological and non-dermatological ailments. Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis.\u00a0In addition, the drug demonstrates anti-inflammatory effects.", "contents": "Dapsone -- Indications. Dapsone is an antibiotic medication\u00a0used in\u00a0multidrug regimens and approved by the United States Food and Drug Administration (FDA) for treating leprosy and dermatitis herpetiformis. Although dapsone was initially researched as an antibiotic agent in 1937, it was first used to treat leprosy in 1945. [1] This drug is available in oral and topical formulations and is also\u00a0prescribed for a range of conditions, including both dermatological and non-dermatological ailments. Dapsone exerts its antimicrobial action by inhibiting bacterial or folic acid synthesis.\u00a0In addition, the drug demonstrates anti-inflammatory effects."}
{"id": "article-20256_4", "title": "Dapsone -- Indications -- FDA-Approved Indications", "content": "Paucobilliairy leprosy Multibaciliary leprosy Dermatitis herpetiformis (in adults) Acne vulgaris (as a topical gel) Off-Label Uses [2] Linear IgA bullous dermatosis, chronic bullous dermatosis of childhood, bullous systemic lupus erythematosus, and erythema elevatum diutinum. Autoimmune bullous dermatoses such as bullous pemphigoid, cicatricial pemphigoid, IgA pemphigus, subcorneal pustular dermatosis, pemphigus vulgaris, pemphigus foliaceous, and epidermolysis bullosa acquisita. Vasculitic dermatoses\u00a0such as leukocytoclastic vasculitis and urticarial vasculitis. Neutrophilic dermatoses such as Sweet syndrome, pyoderma gangrenosum, and Behcet syndrome. Other dermatoses such as subacute cutaneous lupus erythematosus, relapsing polychondritis, granuloma annulare, loxoscelism, granuloma faciale, rosacea, panniculitis, pustular psoriasis, nodulocystic acne, and rhinosporidiosis.", "contents": "Dapsone -- Indications -- FDA-Approved Indications. Paucobilliairy leprosy Multibaciliary leprosy Dermatitis herpetiformis (in adults) Acne vulgaris (as a topical gel) Off-Label Uses [2] Linear IgA bullous dermatosis, chronic bullous dermatosis of childhood, bullous systemic lupus erythematosus, and erythema elevatum diutinum. Autoimmune bullous dermatoses such as bullous pemphigoid, cicatricial pemphigoid, IgA pemphigus, subcorneal pustular dermatosis, pemphigus vulgaris, pemphigus foliaceous, and epidermolysis bullosa acquisita. Vasculitic dermatoses\u00a0such as leukocytoclastic vasculitis and urticarial vasculitis. Neutrophilic dermatoses such as Sweet syndrome, pyoderma gangrenosum, and Behcet syndrome. Other dermatoses such as subacute cutaneous lupus erythematosus, relapsing polychondritis, granuloma annulare, loxoscelism, granuloma faciale, rosacea, panniculitis, pustular psoriasis, nodulocystic acne, and rhinosporidiosis."}
{"id": "article-20256_5", "title": "Dapsone -- Indications", "content": "Non-dermatologic off-label indications include\u00a0a broad spectrum of dermatoses, as well as prevention and treatment of malaria and Pneumocystis jiroveci (previously known as Pneumocystis carinii ). [3]", "contents": "Dapsone -- Indications. Non-dermatologic off-label indications include\u00a0a broad spectrum of dermatoses, as well as prevention and treatment of malaria and Pneumocystis jiroveci (previously known as Pneumocystis carinii ). [3]"}
{"id": "article-20256_6", "title": "Dapsone -- Mechanism of Action", "content": "When treating leprosy, dapsone is bacteriostatic against Mycobacterium leprae at 1 to 10 mg/L. Dapsone\u00a0inhibits the folic acid pathway\u00a0by preventing the bacteria from utilizing para-aminobenzoic acid (PABA) to synthesize folic acid\u00a0by competitively antagonizing PABA.\u00a0Dapsone is also a competitive inhibitor of dihydropteroate synthase. [4]", "contents": "Dapsone -- Mechanism of Action. When treating leprosy, dapsone is bacteriostatic against Mycobacterium leprae at 1 to 10 mg/L. Dapsone\u00a0inhibits the folic acid pathway\u00a0by preventing the bacteria from utilizing para-aminobenzoic acid (PABA) to synthesize folic acid\u00a0by competitively antagonizing PABA.\u00a0Dapsone is also a competitive inhibitor of dihydropteroate synthase. [4]"}
{"id": "article-20256_7", "title": "Dapsone -- Mechanism of Action", "content": "By\u00a0treating conditions with neutrophilic infiltrates in the skin, the drug\u00a0exerts therapeutic activity by affecting neutrophilic functions. Dapsone inhibits the myeloperoxidase-peroxide halide-mediated cytotoxic system, a component of the neutrophil respiratory burst. Through\u00a0this mechanism,\u00a0dapsine controls the degree of\u00a0neutrophil-induced destruction in lesions. In leprosy treatment, dapsone exerts\u00a0the therapeutic effect by inhibiting the folic acid pathway. It also may inhibit the synthesis of chemotactic lipids and interfere with leukotriene (LTB4) mediated chemotaxis in neutrophils and migration to lesions. Dapsone also decreases the adhesion of neutrophils to IgA. [5]", "contents": "Dapsone -- Mechanism of Action. By\u00a0treating conditions with neutrophilic infiltrates in the skin, the drug\u00a0exerts therapeutic activity by affecting neutrophilic functions. Dapsone inhibits the myeloperoxidase-peroxide halide-mediated cytotoxic system, a component of the neutrophil respiratory burst. Through\u00a0this mechanism,\u00a0dapsine controls the degree of\u00a0neutrophil-induced destruction in lesions. In leprosy treatment, dapsone exerts\u00a0the therapeutic effect by inhibiting the folic acid pathway. It also may inhibit the synthesis of chemotactic lipids and interfere with leukotriene (LTB4) mediated chemotaxis in neutrophils and migration to lesions. Dapsone also decreases the adhesion of neutrophils to IgA. [5]"}
{"id": "article-20256_8", "title": "Dapsone -- Mechanism of Action", "content": "Though the actual mechanism of action of dapsone is unknown for dermatologic conditions, the drug does affect human neutrophils, perhaps by moderating the level of damage by neutrophils at the site of lesions and by reducing\u00a0neutrophil migration to those locations.", "contents": "Dapsone -- Mechanism of Action. Though the actual mechanism of action of dapsone is unknown for dermatologic conditions, the drug does affect human neutrophils, perhaps by moderating the level of damage by neutrophils at the site of lesions and by reducing\u00a0neutrophil migration to those locations."}
{"id": "article-20256_9", "title": "Dapsone -- Mechanism of Action", "content": "Dapsone\u00a0may also exert activity\u00a0on eosinophils and monocytes. The efficacy of the drug in conditions like granuloma annulare and eosinophilic cellulitis, in which monocytes and eosinophils have significant roles, respectively, points to this hypothesis. The mechanism of topical dapsone in treating acne vulgaris is unknown.", "contents": "Dapsone -- Mechanism of Action. Dapsone\u00a0may also exert activity\u00a0on eosinophils and monocytes. The efficacy of the drug in conditions like granuloma annulare and eosinophilic cellulitis, in which monocytes and eosinophils have significant roles, respectively, points to this hypothesis. The mechanism of topical dapsone in treating acne vulgaris is unknown."}
{"id": "article-20256_10", "title": "Dapsone -- Mechanism of Action -- Pharmacokinetics", "content": "Pharmacokinetic factors for oral dapsone are as follows: Absorption: Orally ingested dapsone is rapidly and nearly completely absorbed. Dapsone is detectable a few minutes following ingestion and reaches peak concentration in 4 to 8 hours. Distribution: The drug's volume of distribution is estimated\u00a0at 1.5 L/kg. [6]", "contents": "Dapsone -- Mechanism of Action -- Pharmacokinetics. Pharmacokinetic factors for oral dapsone are as follows: Absorption: Orally ingested dapsone is rapidly and nearly completely absorbed. Dapsone is detectable a few minutes following ingestion and reaches peak concentration in 4 to 8 hours. Distribution: The drug's volume of distribution is estimated\u00a0at 1.5 L/kg. [6]"}
{"id": "article-20256_11", "title": "Dapsone -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: The plasma half-life varies between individuals from 10 to 50 hours, with an average of 28 hours. Repeat tests on the same patient return consistent results. Dapsone is hepatically metabolized by the CYP450 enzyme system, specifically\u00a0CYP2E1, and it\u00a0is a CYP2C9 and CYP3A substrate.\u00a0The drug undergoes metabolism from N -acetylation and N -hydroxylation.", "contents": "Dapsone -- Mechanism of Action -- Pharmacokinetics. Metabolism: The plasma half-life varies between individuals from 10 to 50 hours, with an average of 28 hours. Repeat tests on the same patient return consistent results. Dapsone is hepatically metabolized by the CYP450 enzyme system, specifically\u00a0CYP2E1, and it\u00a0is a CYP2C9 and CYP3A substrate.\u00a0The drug undergoes metabolism from N -acetylation and N -hydroxylation."}
{"id": "article-20256_12", "title": "Dapsone -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Approximately 85% of the daily dosage of dapsone is recoverable in the urine as water-soluble metabolites. Dapsone and metabolites are formed in the liver as dapsone glucuronide, which is water-soluble and rapidly excreted via the kidneys. [7] Drug excretion is slow, and a steady\u00a0serum level is maintained with\u00a0indicated dosing.", "contents": "Dapsone -- Mechanism of Action -- Pharmacokinetics. Elimination: Approximately 85% of the daily dosage of dapsone is recoverable in the urine as water-soluble metabolites. Dapsone and metabolites are formed in the liver as dapsone glucuronide, which is water-soluble and rapidly excreted via the kidneys. [7] Drug excretion is slow, and a steady\u00a0serum level is maintained with\u00a0indicated dosing."}
{"id": "article-20256_13", "title": "Dapsone -- Administration -- Available Dosage Forms and Strengths", "content": "Dapsone is available in 25 mg and 100 mg tablets. Topical dapsone is available in 5% and 7.5% gel formulations.", "contents": "Dapsone -- Administration -- Available Dosage Forms and Strengths. Dapsone is available in 25 mg and 100 mg tablets. Topical dapsone is available in 5% and 7.5% gel formulations."}
{"id": "article-20256_14", "title": "Dapsone -- Administration -- Adult Dosage", "content": "Leprosy: According to the World Health Organization Expert Committee on Leprosy: Eighth Report, there are\u00a03 standard first-line drugs: rifampin (rifampicin), clofazimine, and dapsone. These are fixed-duration multidrug regimens, and none should be\u00a0prescribed\u00a0as monotherapy. For multibacillary leprosy, the standard adult dose of dapsone is 100 mg by mouth daily for 12 months. The standard child dose is 50 mg orally daily for 12 months. For paucibacillary leprosy, the standard adult dose of dapsone is 100 mg orally daily for\u00a06 months. The standard\u00a0oral dosage for children is 50 mg daily for\u00a06 months. Children\u00a0younger than\u00a010\u00a0should receive appropriately reduced dapsone dosage at 2 mg/kg body weight per day.", "contents": "Dapsone -- Administration -- Adult Dosage. Leprosy: According to the World Health Organization Expert Committee on Leprosy: Eighth Report, there are\u00a03 standard first-line drugs: rifampin (rifampicin), clofazimine, and dapsone. These are fixed-duration multidrug regimens, and none should be\u00a0prescribed\u00a0as monotherapy. For multibacillary leprosy, the standard adult dose of dapsone is 100 mg by mouth daily for 12 months. The standard child dose is 50 mg orally daily for 12 months. For paucibacillary leprosy, the standard adult dose of dapsone is 100 mg orally daily for\u00a06 months. The standard\u00a0oral dosage for children is 50 mg daily for\u00a06 months. Children\u00a0younger than\u00a010\u00a0should receive appropriately reduced dapsone dosage at 2 mg/kg body weight per day."}
{"id": "article-20256_15", "title": "Dapsone -- Administration -- Adult Dosage", "content": "Dermatitis herpetiformis: In patients who are\u00a0responsive to dapsone, there is a quick reduction in pruritus followed by the clearance of skin lesions. However, there is no effect on the gastrointestinal aspect of the disease. The starting dose for treating dermatitis herpetiformis is 50 mg daily, administered orally, and dapsone should be titrated up to 300 mg daily to achieve the desired effect. A higher dose is given only if the patient is not\u00a0responsive to a lower dose. The dose should be reduced to the minimum effective dose of 50 mg to 300 mg per day as soon as possible to avoid potential adverse effects. Dapsone is not indicated in the pediatric patient for this condition. The dosing schedule for other dermatoses is the same as\u00a0for dermatitis herpetiformis. [8] [9]", "contents": "Dapsone -- Administration -- Adult Dosage. Dermatitis herpetiformis: In patients who are\u00a0responsive to dapsone, there is a quick reduction in pruritus followed by the clearance of skin lesions. However, there is no effect on the gastrointestinal aspect of the disease. The starting dose for treating dermatitis herpetiformis is 50 mg daily, administered orally, and dapsone should be titrated up to 300 mg daily to achieve the desired effect. A higher dose is given only if the patient is not\u00a0responsive to a lower dose. The dose should be reduced to the minimum effective dose of 50 mg to 300 mg per day as soon as possible to avoid potential adverse effects. Dapsone is not indicated in the pediatric patient for this condition. The dosing schedule for other dermatoses is the same as\u00a0for dermatitis herpetiformis. [8] [9]"}
{"id": "article-20256_16", "title": "Dapsone -- Administration -- Adult Dosage", "content": "Acne vulgaris: The dapsone dosage for adults and children aged 12 and older is 5% topical gel applied twice daily. Alternatively, the 7.5% gel can be applied topically once daily. For children aged 9 to 11, apply the 7.5% gel once daily. [10]", "contents": "Dapsone -- Administration -- Adult Dosage. Acne vulgaris: The dapsone dosage for adults and children aged 12 and older is 5% topical gel applied twice daily. Alternatively, the 7.5% gel can be applied topically once daily. For children aged 9 to 11, apply the 7.5% gel once daily. [10]"}
{"id": "article-20256_17", "title": "Dapsone -- Administration -- Adult Dosage", "content": "Pneumocystis (carinii) jiroveci : Dapsone is off-label for the prophylaxis and treatment of P\u00a0jiroveci (carinii), which is classified as a fungus. For prophylaxis, the adult dose is 100 mg daily administered by oral route or divided twice a day as monotherapy.\u00a0Dapsone\u00a0can also be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin. The pediatric dose is also orally administered. For patients older than\u00a01 month, the dose is 2 mg/kg daily, not to exceed 100 mg per day, or 4 mg/kg/dose weekly, not to exceed 200 mg/week. The adolescent dose is 100 mg orally daily or divided twice daily as monotherapy.\u00a0Dapsone\u00a0can be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin. [11]", "contents": "Dapsone -- Administration -- Adult Dosage. Pneumocystis (carinii) jiroveci : Dapsone is off-label for the prophylaxis and treatment of P\u00a0jiroveci (carinii), which is classified as a fungus. For prophylaxis, the adult dose is 100 mg daily administered by oral route or divided twice a day as monotherapy.\u00a0Dapsone\u00a0can also be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin. The pediatric dose is also orally administered. For patients older than\u00a01 month, the dose is 2 mg/kg daily, not to exceed 100 mg per day, or 4 mg/kg/dose weekly, not to exceed 200 mg/week. The adolescent dose is 100 mg orally daily or divided twice daily as monotherapy.\u00a0Dapsone\u00a0can be administered orally at 50 mg daily in combination with weekly pyrimethamine and leucovorin. [11]"}
{"id": "article-20256_18", "title": "Dapsone -- Administration -- Adult Dosage", "content": "To treat P jiroveci, the adult dose is 100 mg daily in combination with trimethoprim for 21 days. The dose is 2 mg/kg daily in conjunction with trimethoprim for 21 days for pediatric patients older than\u00a01 month. For adolescents, the dose is 100 mg daily in combination with trimethoprim for 21 days.", "contents": "Dapsone -- Administration -- Adult Dosage. To treat P jiroveci, the adult dose is 100 mg daily in combination with trimethoprim for 21 days. The dose is 2 mg/kg daily in conjunction with trimethoprim for 21 days for pediatric patients older than\u00a01 month. For adolescents, the dose is 100 mg daily in combination with trimethoprim for 21 days."}
{"id": "article-20256_19", "title": "Dapsone -- Administration -- Adult Dosage", "content": "Toxoplasmosis prophylaxis: Dapsone is also used off-label for prophylaxis against toxoplasmosis. The dose is 50 mg oral each day. It is not considered first-line and should be given with pyrimethamine and leucovorin. [12]", "contents": "Dapsone -- Administration -- Adult Dosage. Toxoplasmosis prophylaxis: Dapsone is also used off-label for prophylaxis against toxoplasmosis. The dose is 50 mg oral each day. It is not considered first-line and should be given with pyrimethamine and leucovorin. [12]"}
{"id": "article-20256_20", "title": "Dapsone -- Administration -- Special Patient Populations", "content": "Hepatic impairment: Hepatic dosing has no specific recommendations, but caution is advised.", "contents": "Dapsone -- Administration -- Special Patient Populations. Hepatic impairment: Hepatic dosing has no specific recommendations, but caution is advised."}
{"id": "article-20256_21", "title": "Dapsone -- Administration -- Special Patient Populations", "content": "Renal impairment: No dose adjustments are necessary for patients with renal impairment. If the patient is on hemodialysis, dosing\u00a0is after dialysis, with consideration\u00a0for a supplemental dose if the subsequent maintenance dose is not due immediately\u00a0after dialysis. Peritoneal dialysis requires no dose adjustment and no supplemental dose.", "contents": "Dapsone -- Administration -- Special Patient Populations. Renal impairment: No dose adjustments are necessary for patients with renal impairment. If the patient is on hemodialysis, dosing\u00a0is after dialysis, with consideration\u00a0for a supplemental dose if the subsequent maintenance dose is not due immediately\u00a0after dialysis. Peritoneal dialysis requires no dose adjustment and no supplemental dose."}
{"id": "article-20256_22", "title": "Dapsone -- Administration -- Special Patient Populations", "content": "Pregnancy considerations: Because\u00a0of the lack of data on pregnancy and the drug's potential teratogenicity, dapsone\u00a0is given to pregnant females only if\u00a0the benefits outweigh the risks. Based on limited data from human studies, there is a risk of teratogenicity and hemolytic anemia. [13]", "contents": "Dapsone -- Administration -- Special Patient Populations. Pregnancy considerations: Because\u00a0of the lack of data on pregnancy and the drug's potential teratogenicity, dapsone\u00a0is given to pregnant females only if\u00a0the benefits outweigh the risks. Based on limited data from human studies, there is a risk of teratogenicity and hemolytic anemia. [13]"}
{"id": "article-20256_23", "title": "Dapsone -- Administration -- Special Patient Populations", "content": "Breastfeeding considerations: There is a potential risk of infant hemolytic anemia based on the drug's mechanism of action and limited data from human studies; therefore, clinicians must assess the risks and benefits for breastfeeding women. [13]", "contents": "Dapsone -- Administration -- Special Patient Populations. Breastfeeding considerations: There is a potential risk of infant hemolytic anemia based on the drug's mechanism of action and limited data from human studies; therefore, clinicians must assess the risks and benefits for breastfeeding women. [13]"}
{"id": "article-20256_24", "title": "Dapsone -- Administration -- Special Patient Populations", "content": "Pediatric patients: Pediatric patients receive treatment using the same schedule as adults but with smaller dosages. No data point\u00a0to dapsone affecting children's later growth and functional development. Dapsone topical is not recommended for children younger than 9. Older patients: No data implicate that dapsone needs special dose adjustments in oral or topical dose forms in older patients.", "contents": "Dapsone -- Administration -- Special Patient Populations. Pediatric patients: Pediatric patients receive treatment using the same schedule as adults but with smaller dosages. No data point\u00a0to dapsone affecting children's later growth and functional development. Dapsone topical is not recommended for children younger than 9. Older patients: No data implicate that dapsone needs special dose adjustments in oral or topical dose forms in older patients."}
{"id": "article-20256_25", "title": "Dapsone -- Adverse Effects", "content": "Adverse effects of oral dapsone include: Hematologic: Hemolytic anemia, aplastic anemia, methemoglobinemia, leukopenia, and agranulocytosis Cutaneous hypersensitivity reactions: Mebilliform eruption,\u00a0exfoliative erythroderma, drug-induced lupus erythematosus, and toxic epidermal\u00a0necrolysis Neurologic: Peripheral neuropathy, predominantly motor loss Psychiatric: Psychosis and insomnia Eyes: Blurred vision Ear, nose, and throat: Tinnitus and vertigo Cardiac: Tachycardia Pulmonary: Pulmonary eosinophilia Hepatic: Hepatitis, dapsone syndrome, cholestatic jaundice, and hypoalbuminemia without proteinuria Gastrointestinal: Nausea, vomiting, abdominal pain, anorexia, and pancreatitis Renal:\u00a0Nephrotic syndrome, albuminuria, and renal papillary necrosis", "contents": "Dapsone -- Adverse Effects. Adverse effects of oral dapsone include: Hematologic: Hemolytic anemia, aplastic anemia, methemoglobinemia, leukopenia, and agranulocytosis Cutaneous hypersensitivity reactions: Mebilliform eruption,\u00a0exfoliative erythroderma, drug-induced lupus erythematosus, and toxic epidermal\u00a0necrolysis Neurologic: Peripheral neuropathy, predominantly motor loss Psychiatric: Psychosis and insomnia Eyes: Blurred vision Ear, nose, and throat: Tinnitus and vertigo Cardiac: Tachycardia Pulmonary: Pulmonary eosinophilia Hepatic: Hepatitis, dapsone syndrome, cholestatic jaundice, and hypoalbuminemia without proteinuria Gastrointestinal: Nausea, vomiting, abdominal pain, anorexia, and pancreatitis Renal:\u00a0Nephrotic syndrome, albuminuria, and renal papillary necrosis"}
{"id": "article-20256_26", "title": "Dapsone -- Adverse Effects", "content": "Dapsone syndrome: Usually develops after 2 to 6 weeks of dapsone therapy. The characteristic presentation is fever, rash, and hepatitis. The clinical picture may resemble infectious mononucleosis. Blood work will show peripheral eosinophilia and elevated liver enzymes. It\u00a0is life-threatening if inadequately treated. [14] The adverse reactions that may occur with topical dapsone include methemoglobinemia, angioedema, dryness, peeling, erythema, and oily skin.", "contents": "Dapsone -- Adverse Effects. Dapsone syndrome: Usually develops after 2 to 6 weeks of dapsone therapy. The characteristic presentation is fever, rash, and hepatitis. The clinical picture may resemble infectious mononucleosis. Blood work will show peripheral eosinophilia and elevated liver enzymes. It\u00a0is life-threatening if inadequately treated. [14] The adverse reactions that may occur with topical dapsone include methemoglobinemia, angioedema, dryness, peeling, erythema, and oily skin."}
{"id": "article-20256_27", "title": "Dapsone -- Contraindications", "content": "The contraindications for dapsone in different formulations are listed below.", "contents": "Dapsone -- Contraindications. The contraindications for dapsone in different formulations are listed below."}
{"id": "article-20256_28", "title": "Dapsone -- Contraindications -- Oral Dapsone", "content": "Absolute contraindications to the use of dapsone are prior hypersensitivity to dapsone or its derivatives, including agranulocytosis and hypersensitivity syndrome. Deaths from agranulocytosis, aplastic anemia, and other blood dyscrasias\u00a0are reported with dapsone administration. [15]", "contents": "Dapsone -- Contraindications -- Oral Dapsone. Absolute contraindications to the use of dapsone are prior hypersensitivity to dapsone or its derivatives, including agranulocytosis and hypersensitivity syndrome. Deaths from agranulocytosis, aplastic anemia, and other blood dyscrasias\u00a0are reported with dapsone administration. [15]"}
{"id": "article-20256_29", "title": "Dapsone -- Contraindications -- Oral Dapsone", "content": "Relative contraindications to using dapsone include allergy to sulfonamide antimicrobials, significant cardiopulmonary disease, significant liver or renal function impairment, glucose-6-phosphate 1-dehydrogenase (G6PD) deficiency, methemoglobinemia, or pre-existing peripheral neuropathy.\u00a0For the treatment of pregnant women, dapsone is a category C drug. Therefore, it should be used cautiously and only if the benefits outweigh the risks. [16]", "contents": "Dapsone -- Contraindications -- Oral Dapsone. Relative contraindications to using dapsone include allergy to sulfonamide antimicrobials, significant cardiopulmonary disease, significant liver or renal function impairment, glucose-6-phosphate 1-dehydrogenase (G6PD) deficiency, methemoglobinemia, or pre-existing peripheral neuropathy.\u00a0For the treatment of pregnant women, dapsone is a category C drug. Therefore, it should be used cautiously and only if the benefits outweigh the risks. [16]"}
{"id": "article-20256_30", "title": "Dapsone -- Contraindications -- Topical Dapsone", "content": "G6PD deficiency\u00a0and methemoglobinemia also represent contraindications to topical dapsone.", "contents": "Dapsone -- Contraindications -- Topical Dapsone. G6PD deficiency\u00a0and methemoglobinemia also represent contraindications to topical dapsone."}
{"id": "article-20256_31", "title": "Dapsone -- Monitoring", "content": "The following monitoring parameters apply to orally administered dapsone.\u00a0Topical dapsone requires no routine monitoring.", "contents": "Dapsone -- Monitoring. The following monitoring parameters apply to orally administered dapsone.\u00a0Topical dapsone requires no routine monitoring."}
{"id": "article-20256_32", "title": "Dapsone -- Monitoring -- Baseline", "content": "Complete history and physical with emphasis on cardiopulmonary, gastrointestinal, neurologic, and renal systems Lab: Complete blood count, differential count, liver function tests, renal function tests, G6PD level, and urinalysis [17]", "contents": "Dapsone -- Monitoring -- Baseline. Complete history and physical with emphasis on cardiopulmonary, gastrointestinal, neurologic, and renal systems Lab: Complete blood count, differential count, liver function tests, renal function tests, G6PD level, and urinalysis [17]"}
{"id": "article-20256_33", "title": "Dapsone -- Monitoring -- Follow-Up", "content": "Complete blood count (CBC) with differential every week for\u00a04 weeks, then every\u00a02 weeks until week 12, then every 3 to 4 months. Reticulocyte count as needed. Liver function tests and renal function tests every 3 to 4 months. Methemoglobin level as clinically indicated.", "contents": "Dapsone -- Monitoring -- Follow-Up. Complete blood count (CBC) with differential every week for\u00a04 weeks, then every\u00a02 weeks until week 12, then every 3 to 4 months. Reticulocyte count as needed. Liver function tests and renal function tests every 3 to 4 months. Methemoglobin level as clinically indicated."}
{"id": "article-20256_34", "title": "Dapsone -- Toxicity", "content": "Dapsone-induced methemoglobinemia typically results from acute\u00a0poisoning,\u00a0either by accidental ingestion or suicidal intent. Presenting symptoms include headache, fatigue, tachycardia, dizziness, and weakness. More severe cases (levels above 60%) can result in arrhythmias, dyspnea, seizures, or coma. Methemoglobinemia is treatable with gastric decontamination, early administration of activated charcoal, or intravenous (IV) methylene blue. [18] [19]", "contents": "Dapsone -- Toxicity. Dapsone-induced methemoglobinemia typically results from acute\u00a0poisoning,\u00a0either by accidental ingestion or suicidal intent. Presenting symptoms include headache, fatigue, tachycardia, dizziness, and weakness. More severe cases (levels above 60%) can result in arrhythmias, dyspnea, seizures, or coma. Methemoglobinemia is treatable with gastric decontamination, early administration of activated charcoal, or intravenous (IV) methylene blue. [18] [19]"}
{"id": "article-20256_35", "title": "Dapsone -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional healthcare team, comprising physicians, advanced practice practitioners, nursing staff, and pharmacists, must collaborate to guarantee patient compliance with dapsone prescriptions. Team members need to communicate and address any severe drug adverse effects the patient may encounter, such as rash and jaundice, during their treatment. Some cases may require an infectious disease specialist and/or an infectious disease specialty pharmacist. These specialists\u00a0are updated with the latest antibiogram data and can recommend dosing adjustments or alternative therapies.", "contents": "Dapsone -- Enhancing Healthcare Team Outcomes. The interprofessional healthcare team, comprising physicians, advanced practice practitioners, nursing staff, and pharmacists, must collaborate to guarantee patient compliance with dapsone prescriptions. Team members need to communicate and address any severe drug adverse effects the patient may encounter, such as rash and jaundice, during their treatment. Some cases may require an infectious disease specialist and/or an infectious disease specialty pharmacist. These specialists\u00a0are updated with the latest antibiogram data and can recommend dosing adjustments or alternative therapies."}
{"id": "article-20256_36", "title": "Dapsone -- Enhancing Healthcare Team Outcomes", "content": "All patient encounters and interventions must be documented in the medical record so that every team member can access the same current and updated information. Open communication can preclude adverse events and make all team members aware of concerns that may arise during monitoring. This interprofessional approach drives optimal patient outcomes.", "contents": "Dapsone -- Enhancing Healthcare Team Outcomes. All patient encounters and interventions must be documented in the medical record so that every team member can access the same current and updated information. Open communication can preclude adverse events and make all team members aware of concerns that may arise during monitoring. This interprofessional approach drives optimal patient outcomes."}
{"id": "article-20256_37", "title": "Dapsone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Dapsone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}